Tennessee Legislature Sends PBM Pharmacy Restriction Bill to Governor Amid CVS Warning of Clinic Closures and Job Losses

Context Pharmacy benefit managers (PBMs) operate as intermediaries in the pharmaceutical supply chain. They manage prescription drug benefits for health insurers, negotiating drug prices and processing claims. The Tennessee legislation specifically aims to restrict the operation of pharmacies directly owned by these PBM companies. Supporters indicate the bill's purpose is to support independent pharmacies across the state. This move reflects a broader national discussion regarding PBMs' influence on drug pricing and market competition.

Key Facts On Tuesday, the Tennessee House of Representatives approved legislation designed to limit pharmacies owned by pharmacy benefit managers. This vote concluded the legislative process, following the Tennessee Senate's passage of the identical bill on Monday. The measure now advances to Governor Bill Lee's desk for consideration.

CVS Health, a company with significant PBM and pharmacy operations, issued a direct response to the bill's passage. The company stated the legislation, despite being presented as an anti-PBM measure, will not result in lower drug costs for consumers. Instead, CVS Health characterized the bill's intent as solely benefiting independent pharmacies.

The company further outlined severe potential consequences for Tennessee. CVS Health warned of the closure of 25 MinuteClinic locations, which provide acute and primary care services statewide. This operational change would directly lead to the loss of more than 2,000 jobs within Tennessee. The company also indicated its readiness to challenge the constitutionality of this new law in federal court, mirroring actions taken in other states.

What It Means The impending decision by Governor Lee will shape the immediate regulatory environment for pharmacies in Tennessee. Should the bill become law, the state could face legal challenges from affected PBM-owned entities, including CVS Health. This legislative action highlights ongoing tensions regarding healthcare competition, drug pricing mechanisms, and the roles of large PBMs versus local pharmacies. Observers will now watch for the Governor's signature or veto, and any subsequent legal proceedings.